摘要
目的评价国产奥氮平治疗以阴性症状为主的精神分裂症的疗效和安全性。方法将80例符合DSM-Ⅳ精神分裂症患者随机分为2组,分别给予奥氮平和喹硫平治疗,疗程共8周,用阳性症状与阴性症状量表(PANSS)、临床疗效总评量表(CGI)评定疗效,药物副反应量表(TESS)评定不良反应。结果奥氮平组显效率87.2%、喹硫平组显效率为81.1%,两药对阴性症状的疗效无显著性差异(P>0.05)。2组在治疗过程中出现较多的不良反应是嗜睡、体质量增加,但两者之间无显著性差异(P>0.05)。结论奥氮平对以阴性症状为主的精神分裂症有较好的疗效,与喹硫平的疗效和不良反应相当。
Objective To compare the efficacy and safety of olanzapine in the treatment of negative symptoms of schizophrenia.MethodsEighty patients diagnosed negative symptoms of schizophrenia by DSM-Ⅳ were randomly allocated to two groups and treated with olanzapine or quetiapine for 8 weeks,respectively.The efficacy and side effects were evaluated by PANSS,CGI and TESS.ResultsThe significant efficacy rates for the olanzapine and quetiapine groups were 87.2% and 81.1%.There was no significant difference in efficacy between the two groups.The rates of side effects were similar in two groups,including lethargy and weight gain.ConclusionThe results suggest that olanzapine is as effective and safe as quetiapine for patients with negative symptoms of schizophrenia.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2012年第4期260-262,245,共4页
The Chinese Journal of Clinical Pharmacology
关键词
奥氮平
喹硫平
精神分裂症
阴性症状
疗效
安全性
olanzapane
quetiapine
negative symptoms of schizophrenia
efficacy
safety
